Search by Title Article Topic - Any -AdvocacyCertificationClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHFSA Annual Scientific MeetingHFSA AwardsHFSA Board Certification ReviewHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterHFSA MembershipIn The NewsIndustryJournal of Cardiac FailureMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Jun 22 2022 | Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil Industry News In The News Industry Read More May 20 2022 | Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil Industry News In The News Industry Read More Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More Apr 22 2022 | Request for Proposals (RFP): Quality Improvement Grants to Support Development of Cardiac Amyloid Centers Industry News In The News Industry Read More Apr 1 2022 | ACC, AHA, HFSA Issue Heart Failure Guideline HFSA News Heart Failure Guidelines In The News Journal of Cardiac Failure Press Release Research Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page Next › Last page Last »
Jun 22 2022 | Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil Industry News In The News Industry Read More
May 20 2022 | Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil Industry News In The News Industry Read More
Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More
Apr 22 2022 | Request for Proposals (RFP): Quality Improvement Grants to Support Development of Cardiac Amyloid Centers Industry News In The News Industry Read More
Apr 1 2022 | ACC, AHA, HFSA Issue Heart Failure Guideline HFSA News Heart Failure Guidelines In The News Journal of Cardiac Failure Press Release Research Read More